Short-Term Intensive Insulin Therapy Could Be the Preferred Option for New Onset Type 2 Diabetes Mellitus Patients With HbA1c > 9%

Journal of Diabetes - United States
doi 10.1111/1753-0407.12581
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Is Insulin the Preferred Treatment for HbA1c >9%?

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2017English

Can Hba1c Be a Marker for Cardiovascular Risk in Type 2 Diabetes Mellitus

International Journal of Medical Research and Review
2015English

Intensive Insulin Therapy as the Primary Treatment for Type 2 Diabetes

Clinical Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2011English

Insulin Therapy for Adult Patients With Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017

Korean Journal of Internal Medicine
Internal Medicine
2017English

Predictors of Sustained Drug-Free Diabetes Remission Over 48 Weeks Following Short-Term Intensive Insulin Therapy in Early Type 2 Diabetes

BMJ Open Diabetes Research and Care
EndocrinologyMetabolismDiabetes
2016English

Cost-Effectiveness of Insulin Degludec Compared With Insulin Glargine for Patients With Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Factors Associated With Poor Sleep Quality Among Type 2 Diabetes Mellitus Patients on Insulin Therapy

Journal of Diabetes Mellitus
2015English

HbA1c as Screening Biomarker of Dyslipidemia in Type 2 Diabetes Mellitus Patients

International Journal of Advances in Medicine
2018English

Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients With Type 2 Diabetes Receiving Basal–Bolus Therapy

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy